---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-018922"
form_type: "8-K/A"
ticker: "SDEV"
cik: "0001389545"
company_name: "Stablecoin Development Corp"
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:07:05.547469+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NovaBay reports pro forma Q1 2024 net loss $2.3M after DERMAdoctor sale; 1:35 reverse split

## Summary
- Pro forma Q1 2024: product revenue $2.6M, net loss from cont. ops $2.3M (vs historical $3.1M).
- FY2023 pro forma: net loss $5.8M (historical $9.6M); revenue reduced $3.6M from discontinued DERMAdoctor.
- 1-for-35 reverse stock split effective May 30, 2024, retroactively applied to pro forma per-share data.
- Cash proceeds from DERMAdoctor sale were $1.07M; pro forma loss on divestiture $0.98M as of Dec 31, 2023.
- Company now solely focused on remaining eye-care operations (Avenova) after divestiture.

## SEC filing metadata
- accession: 0001437749-24-018922
- form_type: 8-K/A
- ticker: SDEV
- cik: 0001389545
- company_name: Stablecoin Development Corp
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1389545/000143774924018922/0001437749-24-018922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1389545/000143774924018922/nby20240531_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-018922
- JSON: https://secwatch.observer/filing/0001437749-24-018922.json
- Plain text: https://secwatch.observer/filing/0001437749-24-018922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.